Univariate Cox proportional hazards models for survival
Variable . | No. patients . | Relative risk . | 95% CI . | P . |
|---|---|---|---|---|
| Diagnosis | ||||
| Precursor B-ALL | 85 | 1.00 | — | — |
| Mature B-ALL | 10 | 1.57 | 0.36-6.88 | .55 |
| Treatment | ||||
| Hyper-CVAD | 45 | 1.00 | — | — |
| Hyper-CVAD + rituximab | 38 | 0.81 | 0.27-2.43 | .71 |
| Hyper-CVAD + imatinib | 12 | 0.87 | 0.23-3.22 | .83 |
| White blood cell count | ||||
| 30 × 109/L or less | 66 | 1.00 | — | — |
| More than 30 × 109/L | 27 | 3.65 | 1.40-9.55 | .008 |
| Karyotype | ||||
| No Ph chromosome | 70 | 1.00 | — | — |
| Ph chromosome-positive | 17 | 1.37 | 0.48-3.97 | .56 |
| Log | ||||
| Age | 95 | 1.62 | 0.53-4.94 | .39 |
| VEGF | 95 | 0.82 | 0.50-1.33 | .42 |
| Greater than 19.1 pg/mL | 82 | 1.00 | — | — |
| 19.1 pg/mL or less | 13 | 4.16 | 1.45-12.00 | .008 |
| bFGF | 95 | 0.80 | 0.47-1.38 | .43 |
| Greater than 9.707 pg/mL | 52 | 1.00 | — | — |
| 9.707 pg/mL or less | 43 | 2.39 | 0.88-6.48 | .086 |
| IL-6 | 93 | 0.84 | 0.55-1.30 | .44 |
| Greater than 4.1 pg/mL | 53 | 1.00 | — | — |
| 4.1 pg/mL or less | 40 | 2.29 | 0.83-6.31 | .11 |
| IL-8 | 95 | 1.15 | 0.73-1.81 | .54 |
| 36.1 pg/mL or less | 63 | 1.00 | — | — |
| Greater than 36.1 pg/mL | 32 | 2.65 | 1.02-6.91 | .046 |
| IL-1Rα | 78 | 1.53 | 0.90-2.59 | .11 |
| 373 pg/mL or less | 47 | 1.00 | — | — |
| Greater than 373 pg/mL | 31 | 4.97 | 1.57-15.70 | .0063 |
| VEGFR1 | 84 | 1.16 | 0.69-1.93 | .58 |
| 482 pg/mL or less | 76 | 1.00 | — | — |
| Greater than 482 pg/mL | 8 | 7.69 | 1.88-31.4 | .0045 |
| VEGFR2 | 89 | 3.31 | 0.65-16.80 | .15 |
| 8222 pg/mL or less | 44 | 1.00 | — | — |
| Greater than 8222 pg/mL | 45 | 3.78 | 1.23-11.60 | .021 |
| TPO | 72 | 1.18 | 0.72-1.94 | .52 |
| 275 pg/mL or less | 24 | 1.00 | — | — |
| Greater than 275 pg/mL | 48 | 3.01 | 0.65-13.90 | .16 |
Variable . | No. patients . | Relative risk . | 95% CI . | P . |
|---|---|---|---|---|
| Diagnosis | ||||
| Precursor B-ALL | 85 | 1.00 | — | — |
| Mature B-ALL | 10 | 1.57 | 0.36-6.88 | .55 |
| Treatment | ||||
| Hyper-CVAD | 45 | 1.00 | — | — |
| Hyper-CVAD + rituximab | 38 | 0.81 | 0.27-2.43 | .71 |
| Hyper-CVAD + imatinib | 12 | 0.87 | 0.23-3.22 | .83 |
| White blood cell count | ||||
| 30 × 109/L or less | 66 | 1.00 | — | — |
| More than 30 × 109/L | 27 | 3.65 | 1.40-9.55 | .008 |
| Karyotype | ||||
| No Ph chromosome | 70 | 1.00 | — | — |
| Ph chromosome-positive | 17 | 1.37 | 0.48-3.97 | .56 |
| Log | ||||
| Age | 95 | 1.62 | 0.53-4.94 | .39 |
| VEGF | 95 | 0.82 | 0.50-1.33 | .42 |
| Greater than 19.1 pg/mL | 82 | 1.00 | — | — |
| 19.1 pg/mL or less | 13 | 4.16 | 1.45-12.00 | .008 |
| bFGF | 95 | 0.80 | 0.47-1.38 | .43 |
| Greater than 9.707 pg/mL | 52 | 1.00 | — | — |
| 9.707 pg/mL or less | 43 | 2.39 | 0.88-6.48 | .086 |
| IL-6 | 93 | 0.84 | 0.55-1.30 | .44 |
| Greater than 4.1 pg/mL | 53 | 1.00 | — | — |
| 4.1 pg/mL or less | 40 | 2.29 | 0.83-6.31 | .11 |
| IL-8 | 95 | 1.15 | 0.73-1.81 | .54 |
| 36.1 pg/mL or less | 63 | 1.00 | — | — |
| Greater than 36.1 pg/mL | 32 | 2.65 | 1.02-6.91 | .046 |
| IL-1Rα | 78 | 1.53 | 0.90-2.59 | .11 |
| 373 pg/mL or less | 47 | 1.00 | — | — |
| Greater than 373 pg/mL | 31 | 4.97 | 1.57-15.70 | .0063 |
| VEGFR1 | 84 | 1.16 | 0.69-1.93 | .58 |
| 482 pg/mL or less | 76 | 1.00 | — | — |
| Greater than 482 pg/mL | 8 | 7.69 | 1.88-31.4 | .0045 |
| VEGFR2 | 89 | 3.31 | 0.65-16.80 | .15 |
| 8222 pg/mL or less | 44 | 1.00 | — | — |
| Greater than 8222 pg/mL | 45 | 3.78 | 1.23-11.60 | .021 |
| TPO | 72 | 1.18 | 0.72-1.94 | .52 |
| 275 pg/mL or less | 24 | 1.00 | — | — |
| Greater than 275 pg/mL | 48 | 3.01 | 0.65-13.90 | .16 |
Ph indicates Philadelphia chromosome; —, not applicable.